AXA 42.970 € (+0,28 %)
EUROPLASMA 0.000 € (0,00 %)
LVMH 397.000 € (-0,33 %)
SAFRAN 317.000 € (0,00 %)
SAINT GOBAIN 66.540 € (0,00 %)
FORVIA 9.018 € (+2,50 %)
SANOFI 71.940 € (-0,30 %)
SBM OFFSHORE 35.320 € (+2,44 %)
DBT 0.061 € (0,00 %)
L'OREAL 407.400 € (+0,14 %)
CARREFOUR 16.610 € (-0,24 %)
PUBLICIS GROUPE SA 102.450 € (-1,25 %)
NN GROUP 76.460 € (+0,92 %)
TRACTIAL 2.580 € (+26,16 %)
CALIBRE 0.000 € (0,00 %)
RENAULT 27.590 € (+3,33 %)
STMICROELECTRONICS 41.170 € (-0,58 %)
SCOR SE 33.760 € (+1,08 %)
PLANISWARE 25.900 € (-1,89 %)
ENGIE 23.420 € (+0,90 %)
VALEO 13.950 € (+1,86 %)
DASSAULT AVIATION 303.800 € (+1,95 %)
SOCIETE GENERALE 64.470 € (-0,20 %)
UMG 16.265 € (+4,30 %)
SHELL PLC 46.880 € (+1,09 %)
BRUNEL INTERNAT 6.950 € (-0,86 %)
BANIJAY GROUP 8.000 € (-2,20 %)
MAUNA KEA TECH 0.114 € (+3,64 %)
SIGNIFY NV 14.590 € (+0,69 %)
KERING 216.950 € (+0,51 %)
VEOLIA ENVIRON. 32.400 € (+0,06 %)
EUROCASTLE INVEST. 14.000 € (+18,64 %)
HEIJMANS KON 82.700 € (+3,25 %)
CREDIT AGRICOLE 15.715 € (+0,45 %)
DSM FIRMENICH AG 107.050 € (-0,37 %)
CHRISTIAN DIOR 433.200 € (+0,46 %)
AKZO NOBEL 59.020 € (-0,24 %)
PHILIPS KON 23.160 € (+1,94 %)
ASML HOLDING 1 477.200 € (+0,89 %)
TECHNIP ENERGIES 30.980 € (+3,47 %)
RELX 34.680 € (+1,29 %)
ORANGE 14.565 € (+0,87 %)
UNILEVER 58.950 € (+1,38 %)
LEGRAND 134.000 € (+0,22 %)
UPERGY 1.645 € (+0,30 %)
LHYFE 1.644 € (-0,36 %)
CORBION 23.120 € (+0,09 %)
PROSUS 35.960 € (+0,03 %)
ARCELORMITTAL SA 56.800 € (+0,21 %)
BOUYGUES 41.510 € (+1,39 %)
KPN KON 4.088 € (+1,36 %)
FUGRO 7.315 € (+2,88 %)
ING GROEP N.V. 30.060 € (+1,49 %)
ENVIPCO HOLDING 3.430 € (0,00 %)
BE SEMICONDUCTOR 155.550 € (-4,80 %)
MEDINCELL 25.720 € (-2,28 %)
AALBERTS NV 41.420 € (+1,07 %)
HAFFNER ENERGY 0.700 € (-4,63 %)
2CRSI 26.240 € (-1,94 %)
DBV TECHNOLOGIES 1.568 € (-3,39 %) |
19/10/2026 00:05
UEG Week 2026: Antibiotic use from childhood linked to higher odds of IBS in young adulthoodEQS-News: UEG Week 2026 / Key word(s): Miscellaneous/Miscellaneous BARCELONA, Spain, Oct. 19, 2026 /PRNewswire/ -- Antibiotic use from childhood through early adulthood is associated with higher odds of irritable bowel syndrome (IBS) at age 24, with the odds increasing as the number of antibiotic prescriptions rose, according to a new study presented today at UEG Week 2026. Researchers analysed data from 2,853 participants in the Swedish BAMSE birth cohort. Antibiotic prescriptions were obtained from the Swedish Prescribed Drug Register from 2005, when participants were aged 9–11 years, until one year before IBS was assessed at age 24. At 24, 10.0% of participants had IBS. Antibiotic use was more common among those with IBS, with 87.8% having received antibiotics compared with 80.2% of those without IBS. After accounting for sex and family socioeconomic status, those who had received antibiotics had 1.5 times the odds of IBS (95% CI 1.0–2.2) compared with those who had not. The odds of IBS increased with the number of antibiotic prescriptions. Compared with those who received no antibiotics, participants receiving one or two prescriptions had 1.3 times the odds of IBS (95% CI 0.9–2.0), rising to 1.6 times (95% CI 1.0–2.4) with three to five prescriptions and 1.7 times (95% CI 1.1–2.6) with six or more. When antibiotic classes were examined, tetracyclines and cephalosporins remained significantly associated with higher odds of IBS after adjusting for sex and family socioeconomic status. Any use of tetracyclines was associated with 1.4 times (95% CI 1.1–1.8) the odds of IBS, while three or more prescriptions of cephalosporins were associated with 6.0 times the odds (95% CI 1.9–18.8). Whilst the study did not investigate why antibiotic exposure was associated with IBS, one possible explanation for the association involves the gut microbiome. Lead author Dr Jessica Sjölund explained, "Previous studies have shown that antibiotics can alter the gut microbiome. As alterations to the gut microbiome are thought to play a role in IBS, this could be one pathway underlying the association observed." Reflecting on the practical implications of the findings, Dr Sjölund stressed the need to balance the essential role of antibiotics with careful prescribing. "Antibiotics remain an important treatment for bacterial infections, and our findings should not discourage their use when they are needed. Rather, they highlight the possibility of longer-term effects from repeated exposure and add to the reasons for avoiding unnecessary antibiotic prescribing."
![]() 19.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. 2417592 19.10.2026 CET/CEST Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière
